Comments to the Food & Drug Administration – Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry

Prepared by NCIA

In September 2020, NCIA’s Policy Council, Hemp Committee, and Scientific Advisory Committee collaborated to submit comments to the Food & Drug Administration in response to a call for guidance on research considerations.

NCIA Filed Amicus Brief – Court of Appeals, Ninth Circuit

Join the movement

NCIA is leading the cannabis industry's unified and coordinated campaign to ensure our business sector is treated fairly and has the opportunity to reach its full potential. Now - more than ever - is the time to invest in your business and the future of the industry by becoming a member.

This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.